A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
2020 ◽
Vol 26
(3)
◽
pp. S274
Keyword(s):
Phase 3
◽
2009 ◽
Vol 9
◽
pp. S87-S96
◽
2014 ◽
Vol 20
◽
pp. 109-118
◽
2001 ◽
Vol 3
(2)
◽
pp. 56-59
◽
Keyword(s):
Keyword(s):
2004 ◽
Vol 42
(12)
◽
pp. 5802-5810
◽
2020 ◽
Vol 5
(3)
◽
pp. 158-176
Keyword(s):
2001 ◽
Vol 39
(4)
◽
pp. 1407-1415
◽